{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:41:51Z","timestamp":1790642511120,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100001116","name":"Foundation Fighting Blindness","doi-asserted-by":"publisher","award":["CD-CL-0619-0758-UMICH"],"award-info":[{"award-number":["CD-CL-0619-0758-UMICH"]}],"id":[{"id":"10.13039\/100001116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005242","name":"Heed Ophthalmic Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00417-021-05508-2","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:03:16Z","timestamp":1641772996000},"page":"1543-1550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis"],"prefix":"10.1007","volume":"260","author":[{"given":"Callie","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Y.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Branham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Schlegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail T.","family":"Fahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiran K.","family":"Jayasundera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naheed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagri G.","family":"Besirli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"5508_CR1","unstructured":"Daiger SP, Rossiter BJF, Greenberg J, Christoffels A, Hide W (2021) RetNet: summaries of genes and loci causing retinal diseases. https:\/\/sph.uth.edu\/RetNet\/. Accessed 2 September 2021"},{"key":"5508_CR2","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.2147\/OPTH.S231804","volume":"14","author":"J Gao","year":"2020","unstructured":"Gao J, Hussain RM, Weng CY (2020) Voretigene neparvovec in retinal diseases: a review of the current clinical evidence. Clin Ophthalmol 14:3855\u20133869. https:\/\/doi.org\/10.2147\/OPTH.S231804","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"5508_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/13816810802626399","volume":"30","author":"X Cai","year":"2009","unstructured":"Cai X, Conley SM, Naash MI (2009) RPE65: role in the visual cycle, human retinal disease, and gene therapy. Ophthalmic Genet 30(2):57\u201362. https:\/\/doi.org\/10.1080\/13816810802626399","journal-title":"Ophthalmic Genet"},{"issue":"6","key":"5508_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/13816810.2018.1533027","volume":"39","author":"V Miraldi Utz","year":"2018","unstructured":"Miraldi Utz V, Coussa RG, Antaki F, Traboulsi EI (2018) Gene therapy for RPE65-related retinal disease. Ophthalmic Genet 39(6):671\u2013677. https:\/\/doi.org\/10.1080\/13816810.2018.1533027","journal-title":"Ophthalmic Genet"},{"issue":"4","key":"5508_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.preteyeres.2008.05.003","volume":"27","author":"AI den Hollander","year":"2008","unstructured":"den Hollander AI, Roepman R, Koenekoop RK, Cremers FP (2008) Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res 27(4):391\u2013419. https:\/\/doi.org\/10.1016\/j.preteyeres.2008.05.003","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"5508_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11095-018-2564-5","volume":"36","author":"T Ong","year":"2019","unstructured":"Ong T, Pennesi ME, Birch DG, Lam BL, Tsang SH (2019) Adeno-associated viral gene therapy for inherited retinal disease. Pharm Res 36(2):34. https:\/\/doi.org\/10.1007\/s11095-018-2564-5","journal-title":"Pharm Res"},{"issue":"5","key":"5508_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.preteyeres.2010.03.004","volume":"29","author":"W Berger","year":"2010","unstructured":"Berger W, Kloeckener-Gruissem B, Neidhardt J (2010) The molecular basis of human retinal and vitreoretinal diseases. Prog Retin Eye Res 29(5):335\u2013375. https:\/\/doi.org\/10.1016\/j.preteyeres.2010.03.004","journal-title":"Prog Retin Eye Res"},{"issue":"9","key":"5508_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1136\/bjophthalmol-2016-309975","volume":"101","author":"N Kumaran","year":"2017","unstructured":"Kumaran N, Moore AT, Weleber RG, Michaelides M (2017) Leber congenital amaurosis\/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions. Br J Ophthalmol 101(9):1147\u20131154. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-309975","journal-title":"Br J Ophthalmol"},{"key":"5508_CR9","unstructured":"Chao DL, Burr A, Pennesi M (2019) RPE65-related leber congenital amaurosis \/ early-onset severe retinal dystrophy. In: Adam MP, Ardinger HH, Pagon RA, et al editors GeneReviews\u00ae. University of Washington, Seattle, WA. https:\/\/www-ncbi-nlm-nih-gov.proxy.lib.umich.edu\/books\/NBK549574\/. Accessed 3 September 2021"},{"key":"5508_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/978-3-319-95046-4_26","volume":"1085","author":"SH Tsang","year":"2018","unstructured":"Tsang SH, Sharma T (2018) Leber congenital amaurosis. Adv Exp Med Biol 1085:131\u2013137. https:\/\/doi.org\/10.1007\/978-3-319-95046-4_26","journal-title":"Adv Exp Med Biol"},{"key":"5508_CR11","unstructured":"US Food and Drug Administration (2017) FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm589467.htm. Accessed 3 September 2021"},{"key":"5508_CR12","unstructured":"Spark Therapeutics (2017) LUXTURNA (voretigene neparvovec-rzyl) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.fda.gov\/media\/109906\/download. Accessed 3 September 2021"},{"key":"5508_CR13","unstructured":"Patel U, Boucher M, de L\u00e9s\u00e9leuc L, Visintini S (2016) Voretigene neparvovec: an emerging gene therapy for the treatment of inherited blindness. In: CADTH issues in emerging health technologies, Canadian Agency for Drugs and Technologies in Health, Ottawa, Ontario, 169."},{"issue":"26","key":"5508_CR14","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1093\/hmg\/10.26.3075","volume":"10","author":"A Auricchio","year":"2001","unstructured":"Auricchio A, Kobinger G, Anand V, Hildinger M, O\u2019Connor E, Maguire AM, Wilson JM, Bennett J (2001) Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 10(26):3075\u20133081. https:\/\/doi.org\/10.1093\/hmg\/10.26.3075","journal-title":"Hum Mol Genet"},{"issue":"10097","key":"5508_CR15","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/s0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA et al (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomized, controlled, open-label, phase 3 trial. Lancet 390(10097):849\u2013860. https:\/\/doi.org\/10.1016\/s0140-6736(17)31868-8","journal-title":"Lancet"},{"key":"5508_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/978-1-4614-3209-8_17","volume":"801","author":"S Zahid","year":"2014","unstructured":"Zahid S, Peeler C, Khan N, Davis J, Mahmood M, Heckenlively JR, Jayasundera T (2014) Digital quantification of Goldmann visual fields (GVFs) as a means for genotype-phenotype comparisons and detection of progression in retinal degenerations. Adv Exp Med Biol 801:131\u2013137. https:\/\/doi.org\/10.1007\/978-1-4614-3209-8_17","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"5508_CR17","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","volume":"126","author":"AM Maguire","year":"2019","unstructured":"Maguire AM, Russell S, Wellman JA et al (2019) Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology 126(9):1273\u20131285. https:\/\/doi.org\/10.1016\/j.ophtha.2019.06.017","journal-title":"Ophthalmology"},{"issue":"3","key":"5508_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/ceo.13022","volume":"46","author":"DC Chung","year":"2018","unstructured":"Chung DC, McCague S, Yu ZF, Thill S, DiStefano-Pappas J, Bennett J, Cross D, Marshall K, Wellman J, High KA (2018) Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clin Exp Ophthalmol 46(3):247\u2013259. https:\/\/doi.org\/10.1111\/ceo.13022","journal-title":"Clin Exp Ophthalmol"},{"issue":"10045","key":"5508_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/s0140-6736(16)30371-3","volume":"388","author":"J Bennett","year":"2016","unstructured":"Bennett J, Wellman J, Marshall KA et al (2016) Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet 388(10045):661\u2013672. https:\/\/doi.org\/10.1016\/s0140-6736(16)30371-3","journal-title":"Lancet"},{"key":"5508_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ajo.2018.09.024","volume":"199","author":"DC Chung","year":"2018","unstructured":"Chung DC, Bertelsen M, Lorenz B, Pennesi ME, Leroy BP, Hamel CP, Pierce E, Sallum J, Larsen M, Stieger K, Preising M, Weleber R, Yang P, Place E, Liu E, Schaefer G, DiStefano-Pappas J, Elci OU, McCague S, Wellman JA, High KA, Reape KZ (2018) The natural history of inherited retinal dystrophy due to biallelic mutations in the RPE65 gene. Am J Ophthalmol 199:58\u201370. https:\/\/doi.org\/10.1016\/j.ajo.2018.09.024","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"5508_CR21","doi-asserted-by":"publisher","first-page":"8070","DOI":"10.1038\/s41598-018-26231-9","volume":"8","author":"K Fujiwara","year":"2018","unstructured":"Fujiwara K, Ikeda Y, Murakami Y, Tachibana T, Funatsu J, Koyanagi Y, Nakatake S, Yoshida N, Nakao S, Hisatomi T, Yoshida S, Yoshitomi T, Ishibashi T, Sonoda KH (2018) Assessment of central visual function in patients with retinitis pigmentosa. Sci Rep 8(1):8070. https:\/\/doi.org\/10.1038\/s41598-018-26231-9","journal-title":"Sci Rep"},{"issue":"6","key":"5508_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130895","volume":"10","author":"Patel DE, Cumberland PM, Walters BC, Russell-Eggitt I, Rahi JS, for the OPTIC Study Group","year":"2015","unstructured":"Patel DE, Cumberland PM, Walters BC, Russell-Eggitt I, Rahi JS, for the OPTIC Study Group (2015) Study of optimal perimetric testing in children (OPTIC): feasibility, reliability, and repeatability of perimetry in children. PLoS ONE 10(6):e0130895. https:\/\/doi.org\/10.1371\/journal.pone.0130895","journal-title":"PLoS ONE"},{"issue":"1","key":"5508_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/13816810.2017.1329447","volume":"39","author":"VS Dedania","year":"2017","unstructured":"Dedania VS, Liu JY, Schlegel D, Andrews CA, Branham K, Khan NW, Musch DC, Heckenlively JR, Jayasundera KT (2017) Reliability of kinetic visual field testing in children with mutation-proven retinal dystrophies: implications for therapeutic clinical trials. Ophthalmic Genet 39(1):22\u201328. https:\/\/doi.org\/10.1080\/13816810.2017.1329447","journal-title":"Ophthalmic Genet"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05508-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-021-05508-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05508-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:08:48Z","timestamp":1649934528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-021-05508-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["5508"],"URL":"https:\/\/doi.org\/10.1007\/s00417-021-05508-2","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"2 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the University of Michigan Institutional Review Board (date 11\/24\/2020\/ no. HUM00104061). All potentially identifying details were omitted and data anonymized in the materials for submission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Cagri G. Besirli has received clinical trial support from Spark Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}